Allogeneic CD34+-enriched and CD45RA-depleted PBSCs

This is an engineered allogeneic peripheral blood stem cell (PBSC) graft product developed by the Fred Hutchinson Cancer Center for the prevention of graft-versus-host disease (GVHD) in patients undergoing hematopoietic cell transplantation. The manufacturing process involves a two-step immunomagnetic selection using the CliniMACS system: first, CD34+ hematopoietic stem cells are positively selected to ensure robust engraftment, and second, CD45RA+ naïve T cells are selectively depleted. By removing naïve T cells—which are the primary drivers of GVHD—while retaining memory T cells, the graft provides rapid immune reconstitution and maintains anti-pathogen and anti-leukemia activity with a significantly reduced risk of chronic GVHD. This cell therapy modality was developed by Dr. Marie Bleakley and has been primarily evaluated in patients with acute leukemia or myelodysplastic syndrome (MDS).

Other names

CD45RA-depleted PBSCsCD-45RA-depleted PBSCsCD 45RA-depleted PBSCsCD45RA-depleted peripheral blood stem cellsCD-45RA-depleted peripheral blood stem cellsCD 45RA-depleted peripheral blood stem cellsNaïve T-cell depleted PBSC graftEngineered allogeneic PBSC graft